Member Info for CTSFO

The accounts will be time and date stamped to mark their completion and release. LUNN is being particularly stupid if he delays their public publication.

Day 349 in the Big Brother House. Everyone is in the diary room…

Why it’s time to invest in mining. Podcast.

https://www.youtube.com/watch?v=vVo-_vgm_vc

The traders can’t resist a 20% profit. It’s just what they do. I’d be happy with small, sustained, day on day climbs in sp. This company is now well financed. It’s negotiating from a position of strength if anyone fancies taking it over. It’s primed and ready to get the drilling done once approval is given. It can now afford to get this done very quickly.

Hugely undervalued at present, but that’s just my opinion.

Tiger, I hope you make life changing amounts here.

Tiny total share issue and free float certainly hurts the sp with these small sells.

A couple of things…

“ There are structural changes in the competitive landscape within the European pelvic floor device market, driven by two of the market's major players. One has withdrawn entirely from the European market, while another has transferred its product portfolio to a business with no current European presence. The structural impact is believed to affect around 70% of an estimated market of more than €25 million. These products will still require to be sourced by hospitals. ABISS 's customers should benefit from this opportunity, but ABISS is also seeking to expand its distribution networks for its own product range. ABISS has manufacturing capacity to supply a significantly larger market share, and as an indication of the operational gearing within the business, it has historically achieved a 30% net margin on revenues of over €3 million.”

“ Business review

Since the equity fund raise in December 2023, significant progress has been made by the business in its objectives of growing the contract manufacturing business and controlling costs. The progress and potential have been accelerated through the purchase of ABISS and deepening relationships with major customers allowing a shorter pathway to profitability. Over the same period, little of the progress made by the Company has been reflected in the share price, and indeed it has not progressed from the heavily discounted price of the fund raise.”

Please excuse the bigish copy and paste. Are we going to see more focused PR and comms off the back of ABISS? If RUA can fill the void in the European market, that would be a ‘F me’ RNS. Fingers crossed their sales teams are making progress.

Happy Hump Day everyone.

I think you’re right. As Rivaldo posted from the Cavendish note:

“FYI Cavendish's latest note last week post-interims retained their 50p target price.

They forecast the £3.8m cash pile reducing to £2.9m this September and then rising to £3.2m next year, against the £8.1m m/cap, and summarise as follows:”

IV, good morning, “ but it would be reasonable to believe that a major could get things moving through regulators a lot quicker than a minnow could.”

This sentence made me stop and think about the company in general. I couldn’t agree more with you. The majors have everything in-place, and possibly in-house where appropriate, to develop implantable devices. The buildings, the equipment, the Human Resources. Possibly the animal experiment facility. The costs of this are relatively small in comparison to the turnover of a major. Most importantly, they know how to get it right first time. Tbf, RUA seem to have found out the hard way how difficult and expensive this is. But, thankfully, RUA are not a one trick pony depending on one product to make or break them - not like some research pharma companies. We’re not dependent on placings, CLNs, loans etc to keep the lights on. To me, this means RUA can’t be forced or rushed into a low ball value sell. They know what they have is worth top dollar, and they can afford to wait. The change in focus of the company was inspired.

Hope everyone is having a great weekend.

They’re searching the back of the sofa to pay for the RNS.

BEHAVE!! 🤣🤣🤣🤣🤣

Tbf it’s a form RNS. The bog standard contact details are given. No one is showing as the author of the RNS. Probably the office cat.

Sp of 20p gives an mcap of £422,000,000. I think that’s unlikely to occur in 6 months. Well happy if wrong!

Langland, excellent memory! That’s very reassuring. The big players: Johnson & Johnson, Ethicon, Coloplast etc: faced significant lawsuits following the SUI treatment failures. None of them will want to repeat this. Interestingly, PTFE derived tapes were trialed against polypropylene. They were preferred by patients but didn’t have the long term structural success of polypropylene. Once approved, the RUA product has the potential to become the global standard. It should combine the advantages of polypropylene without the side effects profile.

In other news:

The heart valve work has quietly been put on the back burner. But not stopped. I wonder how many cycles, or beats, the accelerated wear testing has subjected the trial leaflets to? All very important data for AurTex as an implantable material in general.

Avoiding the normal AIM bb hyperbole, the big players in this industry have got to aware of RUA. At what point do they decide they need the company within their portfolio?

Lovely Jubbly, this time next year…

Hmmm…

Hmmmmmmm…

Cream or Jam on a scone first?

Some of the research into why polypropylene failed:

https://www.sciencedirect.com/science/article/pii/S1751616124003540

I’ll stop monopolising posts now! 😇🙏

Oops, sorry,

https://resolution.nhs.uk/vaginal-mesh/

Hi everyone, sorry if teaching people to suck eggs. Significant harm has been caused to some patients with the use of tension free vaginal tape surgery. The surgery has used polypropylene mesh ‘tape’ as a structural support to treat urinary stress incontinence. The problems and post operative complications resulted in NHS England severely restricting the use of the procedure. An inquiry into the issue was also launched, see below.

My question: is AurTex a better and safer product to allow this surgery to recommence? The surgery wasn’t the problem, the behavior of the implant was. It won’t be cheap to go through the safety procedures to bring the device to market, but if safe, there is a huge patient population that needs help.

Rivaldo - THANK YOU! ✊🏻🫵🏻🙏

I’ve looking for this all morning.

Morning all. Very fair comments about the website. It’s not too expensive to spruce it up.